NEW YORK (GenomeWeb News) – Quintiles and London Genetics have struck a partnership to provide biomarker and pharmacogenomics consulting and services to biopharmaceutical firms, Research Triangle Park, NC-based Quintiles said today.
The two companies will collaborate to provide pharmacogenetic solutions, including novel biomarker and assay development services.
"Ultimately, our alliance will support biopharma in their interactions with academic partners and the development of personalized medicines," London Genetics CEO Dominique Kleyn said in a statement.
Among the services provided by Quintiles are biomarker tests that analyze genes and proteins that affect cell growth and mutation.
London Genetics helps companies to apply genetic knowledge that can take risk out of clinical trials. It also designs and manages projects and patient cohorts through partnerships with relevant academics and clinicians.
Thomas Wollman, senior VP of Quintiles Global Central Laboratories, said that the two firms have "expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world."